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Over the past decades, early diagnosis, new drugs and more personalised multi-modality
treatment have led to impressive increases in survival rates of patients with cancer. This
success in treating cancer has resulted in a large and rapidly increasing number of cancer
survivors, yet life after cancer is often compromised by a broad spectrum of late adverse
treatment effects. Some encounter cardiovascular, second malignancies, cognitive or other
morbidities which impair normal life in an important way. Some patients are confronted
with societal discrimination due to slower performance, chronic fatigue or partial inability
and these things can adversely affect employment, education, insurance or mortgage
opportunities.
In 2012, the European Organisation of Research and Treatment of Cancer (EORTC) Survivor-
ship Task Force was created to focus research efforts on late morbidity of cancer treatment
and its impact on society. On 30–31st January 2014, the 1st EORTC Cancer Survivorship
Summit was organised to facilitate interaction between clinicians, researchers, social
workers, patients, insurers, bankers and policy makers. This important event addressed
the needs of cancer survivors, and new collaborations between academic groups, patient
advocates, financial and political representatives were formed to guide future European
research and health policies in this field. This special issue of the European Journal of Can-
cer is entirely dedicated to this Summit and addresses, respectively, second malignancies,
cardiovascular disease, cognitive dysfunction, infertility/sexuality and psycho-social
problems following cancer treatment.
 2014 European Organisation for Research and Treatment of Cancer. Published by Elsevier
Limited. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).1. Introduction there are over 13 million cancer survivors in the United StatesOver the past decades, the introduction of screening, new
drugs and more personalised multi-modality treatments have
led to impressive increases in survival rates of patients with
cancer. This success in treating cancer has resulted in a large
and rapidly increasing number of cancer survivors. Currently,and close to 30 million survivors worldwide [1,2]. Some five
million are survivors of breast cancer and there are also over
three million survivors each of prostate and colorectal can-
cers. In the United States and Europe the overall 5-year rela-
tive survival rate for all cancers combined has increased
steadily over the past few decades and reached 66.1% for
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for the majority of patients suffering from breast, colorectal
and testicular cancer, Hodgkin’s disease or children’s leukae-
mia, with survival rates reaching 90%. Also many other can-
cer patients are now successfully treated. Even in the
metastatic setting, salvage and maintenance treatments cre-
ate long-term control and reduce this mortal cancer into a
chronic disease.
2. Cancer survivors face a host of issues
Cancer patients face numerous challenges which were
unforeseen in the 70’s, when a diagnosis of cancer was seen
as a death sentence. Clinical trials were focused on more
aggressive treatment to increase survival. Since the 90’s,
starting mainly in paediatric oncology, cancer survivorship
issues became clearer, and new trials trying to reduce treat-
ment toxicity were introduced. Still, long-term toxicity data
remain scarce.
Many cancer survivors face secondary problems for which
neither standard oncology follow-up care nor society as a
whole is well prepared. Some patients encounter disabling
neurological problems, second malignancies, severe cardio-
vascular or other morbidities, which impair normal life in
an important way. Some patients are confronted with difficul-
ties of societal discrimination due to slower performance,
chronic fatigue, partial inability or credit history, and these
things can interfere with their efforts to gain employment,
receive an education, insurance or a mortgage to purchase a
home.
The increasing number of reports on morbidity and mor-
tality due to physical and mental impact of cancer treatment
raises questions concerning the classical follow-up of cancer
patients by cancer specialists. Following the example of pae-
diatric oncology, preventive care plans are being developed
for adult cancer survivors in an effort to reduce morbidity
and early mortality due to late effects. However, many ques-
tions regarding risk assessment and potential interventions
still stand open.
Given the steadily growing volume of cancer survivors, the
definition of follow-up after cancer treatment urgently needs
renewed discussion in order to reduce the economic impact
of high secondary medical consumption due to late adverse
effects. Restructuring follow-up needs to be discussed among
cancer specialists, psychologists, social workers, and also epi-
demiologists, general practitioners, policy makers and health
insures so that appropriate guidance is available for future
cancer survivors.
3. EORTC Cancer Survivorship Task Force
The EORTC (European Organisation for Research and Treat-
ment of Cancer) is a pioneer in cancer care. It has created
European-wide collaborations that are responsible for a
large number of modern cancer treatment protocols. For
over 50 years the EORTC has contributed to better outcome
and quality of life for patients with cancer, and the existing
EORTC network and expertise together with an extensive
database of clinical studies performed over these five dec-ades can also be of great value in increasing our under-
standing of the situations and needs of cancer survivors.
The EORTC wants not only to contribute by collecting
detailed information on late morbidity and mortality, but
also by helping to improve data-collection, statistical mod-
elling, and international cooperation across Europe. In order
to address the needs of cancer survivors, high quality
research of late effects is needed, and this requires access
to large clinical cohorts of homogenously treated cancer
patients who have been prospectively followed for many
years. Such long term follow-up can only be achieved by
independent academic research organisations operating
within a Pan-European framework.
The mission of the EORTC Cancer Survivorship Task Force
is to identify the needs of cancer survivors and provide guid-
ance for their proper management. A team of interested
investigators has joined this Survivorship Task Force and
aims to evaluate the most common problems in cancer survi-
vors and construct research initiatives within the different
EORTC disease oriented research groups as well as other
international working parties.
First, though, we should define what is meant by a cancer
survivor, because there is some variability in the definitions.
For example, the United States National Cancer Institute
(NCI) defines a cancer survivor as any person with cancer,
starting from the moment of diagnosis [4]. Fokor its estimates
on cancer prevalence, the International Agency for Research
on Cancer (IARC) categorises it according to three different
phases of cancer care: initial treatment (within one year),
clinical follow-up (two to three years) and cure (four to five
years) [2].
The EORTC Cancer Survivorship Task Force will use the
term survivorship to describe patients who have completed
their primary treatment (maintenance treatment can be on-
going). The initial focus of this initiative will be on adult can-
cers and primarily lymphoma, breast, colorectal, prostate,
gynaecological and testicular cancers. Patients who are not
cured but in remission for extended periods of time can be
included in this definition in light of the broad emphasis on
quality of life (QoL) and treatment related morbidity in this
category of chronic patients.
4. Progress beyond the state-of-the-art
Using EORTC clinical research data and long term follow-up,
we hope to precisely estimate the magnitude of cancer survi-
vors’ problems, individual risk factors and susceptibility. Pos-
sible preventive measures and guidelines for proper
management are an important goal.
Two main research strategies will be initiated in parallel:
• First, retrospective collection and analyses of cancer survi-
vor data will be developed in a variety of projects. In collab-
oration with the EORTC QoL Group, special updates with
medical, socio-economic and QoL questionnaires will be
developed and validated.
• Second, adoption of prospective long term follow-up in
current and new clinical trials is needed to allow system-
atic and comprehensive collection of data related late
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identify risk groups on a molecular basis and individual
susceptibility.
The strategic plan of the EORTC cancer survivorship
project includes:
1. Provide more insight into late adverse effects of mod-
ern cancer treatments by stimulating and centrally
coordinating diverse research efforts in retrospective
analysis of long-term survivors treated in EORTC con-
ducted clinical randomised trials across different
tumour-oriented groups.
2. Collect data directly from the patients in various
European countries using the EORTC network. Enable
surveys on topics such as fatigue, cognitive and repro-
ductive function and other socio-economic and quality
of life questions. Integration in prospectively upfront
planned long-term follow-up in clinical trials and self-
reporting tools will be proposed to improve comprehen-
sive collection of data.
3. Develop QoL core questionnaires for cancer survivors
addressing medical, socio-economic and quality of life
issues in collaboration with the EORTC QOL Group in
order to directly ask cancer survivors about their
experiences.
4. Conduct case–control studies for analyses of late mor-
tality and morbidity and their relation to dose and plan-
ning of different chemotherapy agents, targeted
therapy, hormonal treatment and radiotherapy.
5. Develop prediction scores for risk of different physical
and mental late adverse events based on age, sex,
country, pre-existing co-morbidity and life-style factors.
6. Collate information on the current management of Euro-
pean cancer survivors and provide insight into barriers
to good health care. Improve communication among dif-
ferent academic, national and international working
groups performing research on survivor’s issues and join
forces by sharing data to complete registries and series of
long-term data in different countries.
7. Create awareness and guidelines in post-cancer care.
Identify barriers, because interaction is needed with
primary health care professionals, patient advocates
and also insurance, banking, health care industry rep-
resentatives, politicians and economists, and, after
having completed problem definitions and risk profiling
follow-up, preventive care programs can then be
improved and addressed in terms of cost-effectiveness.
8. Translational research on materials retrospectively
retrieved or prospectively collected to identify risk
groups and individual susceptibility for developing late
effects.
9. Develop an open access website for researchers to com-
municate, improve data-collection and share patient
information on prevention and health promotion,
expert opinions, publications and harmonised guide-
lines. Sponsoring can be communicated and shared
on the web-based platform, as can presentations of
the outcomes of projects.10. Through workshops and meetings, the Cancer Survi-
vorship Task Force can convene leading experts and
share knowledge to a broader medical community, as
well as health care economists, policy makers and
patient associations.
11. By being an international initiative, collaboration can
take advantage of different national strengths, combine
them, and compare morbidity, care plans, and preven-
tive strategies and produce high quality and unique
research which is difficult to accomplish in other parts
of the world because of the lack of follow-up or treat-
ment accessibility.
5. 1st EORTC Cancer Survivorship Summit
The EORTC Board together with the EORTC Cancer Survi-
vorship Task Force organised the 1st EORTC Cancer Survi-
vorship Summit on 30–31 January 2014 in Brussels,
Belgium. Experts in the field of late adverse effects
research were brought together alongside policy makers,
insurers and cancer survivors to discuss priorities for
future research, guideline development and international
networking. Meetings held prior to the summit enabled
international experts and speakers to discuss and prepare
the plenary sessions focused on late effects such as neuro-
logical effects, second malignancies, issues concerning fer-
tility and sexuality, as well as cardiovascular complications
and psychological and socio-economic impact of cancer
treatment.
During the Summit the state of the art, but moreover
future research directions, were shared with patient advo-
cates, representatives of insurance companies, policy makers
and the rest of the audience via key-note lectures and round
table discussions. Speakers from North America and Europe
outlined various topics concerning life after cancer and
stressed the need for international collaboration and new
economic vision. Measures such as survivorship care plans
and behavioural and life-style interventions were discussed.
Assessment of QoL, optimal methods for data collection and
innovative informatics tools were addressed. The closing ses-
sion illustrated the need for collaboration and organisation of
survivorship research in Europe, for which the EORTC, as a
multidisciplinary and pan-European organisation, can be of
great value.
6. Setting the stage for discussing cancer
survivorship issues
The EORTC stresses the importance of survivorship issues
and is playing an active role in fostering future research
and developing guidelines. By uniting experts in the field
and facilitating their interaction with patients, survivors,
insurers, bankers and policy makers, future lines of
research can be developed faster and be better adapted to
the realities of life after cancer. In this new era of success-
ful cancer treatments which have redefined cancer from a
lethal to a curable or chronic disease, the EORTC has broad-
ened its scope of responsibility beyond improvement of life
4 E J C S U P P L E M E N T S 1 2 ( 2 0 1 4 ) 1 –4expectancy to include survivorship issues, and by the
EORTC Cancer Survivorship Task Force, has combined
forces to address survivorship issues prospectively and sys-
tematically and guide future research and health policies in
Europe in this field.
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